Bristol-Myers Squibb/$BMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Ticker
$BMY
Sector
Trading on
NYSE
Industry
Pharmaceuticals
Headquarters
Employees
34,100
ISIN
US1101221083
Website
BMY Metrics
BasicAdvanced
$99B
18.27
$2.67
0.41
$2.44
5.08%
Price and volume
Market cap
$99B
Beta
0.41
52-week high
$63.33
52-week low
$39.35
Average daily volume
16M
Dividend rate
$2.44
Financial strength
Current ratio
1.279
Quick ratio
1.095
Long term debt to equity
272.495
Total debt to equity
293.85
Dividend payout ratio (TTM)
90.59%
Interest coverage (TTM)
5.48%
Management effectiveness
Return on assets (TTM)
7.24%
Return on equity (TTM)
31.99%
Valuation
Price to earnings (TTM)
18.27
Price to revenue (TTM)
2.078
Price to book
5.71
Price to tangible book (TTM)
-3.7
Price to free cash flow (TTM)
7.565
Dividend yield (TTM)
5.00%
Forward dividend yield
5.08%
Growth
Revenue change (TTM)
4.62%
Earnings per share change (TTM)
-188.94%
3-year revenue growth (CAGR)
0.48%
3-year earnings per share growth (CAGR)
-1.83%
3-year dividend per share growth (CAGR)
5.81%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
BMY News
AllArticlesVideos
Pharma may face more fundamentally negative headlines ahead, says Mizuho's Jared Holz
CNBC Television·22 hours ago
Bristol Myers Squibb CEO on $11B cancer drug deal with BioNTech
CNBC Television·1 day ago
Bristol Myers CEO on Biontech deal: Next new frontier in treatment of cancer
CNBC Television·1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $99B as of June 03, 2025.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 18.27 as of June 03, 2025.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of June 03, 2025, the dividend rate is $2.44 and the yield is 5.08%. Bristol-Myers Squibb has a payout ratio of 90.59% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment date is unconfirmed.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.